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Abstract
Rationale and Objectives. Solid tumor measurements are regularly used in clin-
ical trials of anticancer therapeutic agents and in clinical practice managing pa-
tients’ care. Consequently studies evaluating the reproducibility of solid tumor
measurements are important as lack of reproducibility may directly affect patient
management. The authors propose utilizing a modified Bland-Altman plot with
a difference metric that lends itself naturally to this situation and facilitates in-
terpretation. Materials and Methods. The modification to the Bland-Altman plot
involves replacing the difference plotted on the vertical axis with the relative per-
cent change (RC) between the two measurements. This quantity is the same one
used in assessing tumor response to therapeutic agents and is very familiar to ra-
diologists and clinicians working with cancer patients.The distribution of the RC
is explored and revised equations for the limits of agreement (LoA) are presented.
These methods are applied to positron emission tomography (PET) data studying
two radiotracers. Results. The RC can be calculated separately for each lesion
measured or at the patient level by summing over lesions within patient. In both
cases, the distribution of the RC is highly skewed and is approximated by a neg-
ative shifted lognormal distribution. The standard equations for the 95% LoA
assume the differences are approximately normally distributed and are not appro-
priate for the RC. Conclusions. The modified Bland-Altman plot with correctly
calculated LoA can aid in evaluating agreement between solid tumor measure-
ments.
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1. Introduction
The Bland-Altman plot is a graphical tool that is frequently used to evaluate reproducibility and re-
peatability. In its original and most typically used form, it is constructed by plotting the differences between
two measurements, d = X1 −X2, by the mean of the measurements, 12 (X1 +X2). To accompany the plots,
analysts usually present the 95% limits of agreement (LoA) which are defined d¯±1.96s where d¯ is the average
difference and s is the standard deviation of d [1, 2].
Here we are concerned with the application of Bland-Altman plots to evaluating agreement between
solid tumor measurements. Serial measurements of solid tumors are used to gauge whether a tumor is
responding to an anti-cancer therapeutic agent both when managing a patient’s care and when testing new
treatments in clinical trials. This assessment is most frequently done using the change in tumor size as seen
on anatomic imgaing. Under guidelines established for evaluating response in solid tumors using anatomic
imaging [3, 4], the relative percent change in tumor size measured at a baseline, pre-treatment time, say XB ,
and a follow-up time after treatment has commenced, XF , is calculated as RC= 100× XB−XFXB . In patients
who have multiple tumors measured, XB and XF are taken to be the sums of the tumor measurements
at each time and signify patients’ tumor burden. This continuous RC is usually divided into four response
categories representing patients with a complete response, with a partial response, with stable disease,
and with progressive disease. Non-anatomic serial measurements of solid tumors from 2-[18F]Fluoro-2-
deoxyglucose positron emission tomography (FDG-PET) are also used to evaluate tumor response in a more
limited but growing number of oncologic settings [5]. While currently there is variability across studies in how
tumor response is quantified using FDG-PET (e.g. measurements could be quantified with different metrics
such as the maximal standardized uptake value (SUVmax), total lesion glycolysis, or SUV normalized to
lean body mass to name a few), it has been suggested that the relative change from the baseline value should
be used to quantify tumor response [6].
Many papers have looked at the reproducibility or repeatability of solid tumor measurements. While some
of these papers focus on inter- and intra-observer agreement for the four response categories (using a kappa
statistic, for example), multiple papers report on the agreement for the continuous measurements made on
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individual tumors. Given the previous studies and the recent calls by some that tumor response assessment
in clinical trials should move away from the response categories and consider the change in tumor mea-
surements on a continuous scale [6–10], it is important to ensure that agreement between continuous tumor
measurements be analyzed using appropriate statistical methods which allow for meaningful interpretations.
In reviewing the literature both in clinical and radiology journals, we noted multiple cases where Bland-
Altman plots and LoA were presented to look at agreement between solid tumor measurements. (For some
recent examples, see [11–19].) Across the literature, there was variation in how the plots and LoA were
constructed. While the method originally suggested by Bland and Altman uses the differences, d, there is
no reason why the Bland-Altman plots and LoA cannot be based on other quantities that may be more
useful in other situations. Some of these papers took advantage of this fact and present plots using other
quantities. It appears, however, that there is a lack of consistency in how researchers looking at agreement
in tumor measurements analyze such data. Moreover, in many papers there were errors in the calculation of
the LoA.
The validity of LoA intervals depends on certain assumptions being met. In papers following their original
publications suggesting the use of these plots, Bland and Altman point out that the calculation of the LoA as
they initially presented it assumes that the pairs of measurements used in the calculations are independent
across the observations [20, 21]. That is, suppose that X1 is the first measurement (e.g. the measurement
made by the first reader or at the first read) and X2 is the second measurement (by the second reader or at
the second read). Then the pair of measurements for the ith observation is denoted as (X1i, X2i). Bland and
Altman’s point is that the standard LoA calculation assumes that (X1i, X2i) is independent of (X1j , X2j)
for i 6= j. In our situation, if the observations consist of measurements made on multiple tumors within the
same individual, the observations are correlated and the assumption of independence is violated. Although
there have been a couple of papers discussing how to compute the LoA appropriately accounting for this
correlation [20–22], we have not seen any examples of this methodology being used with measurements of
tumor size. A second assumption made in the definition of the LoA is that the differences, d, are normally
distributed. With studies basing their analysis on metrics other than d, there is a need to ensure that the
distribution assumed in calculating the intervals aligns with the distribution of the chosen metric. If the
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wrong distribution is used, the interval does not yield 95% coverage. In other words, while the idea behind
the 95% LoA is that we expect 95% of the differences (however “difference” is measured) to be within the
95% LoA, if the interval is not properly constructed then it is likely that a substantially lower (or, in some
cases, higher) proportion of the differences may fall into the interval.
In light of these observations, we suggest a clinically relevant metric upon which to base Bland-Altman
plots and the corresponding LoA when evaluating agreement between replicated tumor measurements. We
also explore its distribution and suggest methods for constructing appropriate LoA. These methods are
applied to data collected on prostate cancer patients imaged with PET using two different radiotracers.
2. Methods
While the differences X1 − X2 may be the most relevant quantity to study in some situations, within
the context of tumor response assessment we suggest that the more useful quantity to work with is RC.
This quantity is the one that is used to make clinical decisions on a daily basis. Recall that we conclude
that the inter- or intra-observer agreement is acceptable if the differences within the LoA are not clinically
important. While some clinicians and radiologists may be able to look at X1−X2 and evaluate whether the
differences are sufficiently small or unacceptably large, using RC as the metric translates the results of the
analysis onto a scale that facilitates interpretation and permits a wider audience to have a better sense of
the impact on clinical decision making. In other words, it allows a direct interpretation in terms of the most
clinically relevant quantity.
We note that this is not an entirely novel suggestion. Others have published papers looking at the
agreement in tumor measurements by plotting RC in place of X1−X2 in Bland-Altman plots [15, 18, 19]. This
approach, however, is not consistently used. Furthermore, difficulty lies in how to appropriately construct
the LoA when using a fraction to quantify change instead of the simple difference. In our experience, tumor
measurements are not normally distributed and the distribution of RC is not symmetric. Hence, estimating
the LoA by taking the average RC and adding and subtracting a factor of 1.96 times the standard deviation
of RC likely results in an interval that does not give the stated coverage. Below we suggest more appropriate
methods for obtaining the LoA based on RC. We distinguish the cases depending on whether single or
multiple tumors are being considered for each patient.
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2.1. One tumor per patient
When only one tumor per patient is being used to evaluate reproducibility, there is a single pair of
measurements, (X1i, X2i), for the i
th patient and the pairs are independent across patients. Similar to what
others have observed [7, 8], in the applications we have studied we find that a lognormal distribution is a
reasonable approximation for the distribution of tumor measurements. If X1 and X2 both follow lognormal
distributions, then their ratio, X2X1 , also has a lognormal distribution. The distribution of RC, which can be
rewritten as RC = 100−100× X2X1 is called a negative shifted lognormal distribution [23] or simply lognormal
[24].
To obtain the 95% LoA for RC, let Y = ln (1 − RC100 ). Calculate the sample mean of Y , y¯, and the
sample standard deviation of Y , s. The 95% LoA are then 100 × (1 − ey¯±1.96s). To obtain the LoA for
other probability levels, the value of 1.96 is changed by taking different quantiles from the standard normal
distribution.
2.2. Multiple tumors per patient
We discuss two options for analyzing RC when there are multiple lesions per patient. The first option is
to keep each lesion as a separate observation. RC is calculated as above and each tumor is represented as a
single point on the Bland-Altman plot. In contrast, the estimate of the variance of RC used in the LoA is
different from above accounting for the clustering of lesions within patient. The second option is to calculate
the relative change in total measured tumor burden between the replicated measurements by summing up
tumor measurements at each time. This metric is in fact what is suggested by RECIST [3] and what is
typically used in clinical practice. In this case, each point on the Bland-Altman plot represents a patient
and both the definition and the distribution of the relative change are different from above. We describe
this approach in further detail below.
2.2.1. Tumors as the unit of analysis
We use l to denote lesions with l = 1, ..., ni where ni is the number of lesions measured for the i
th patient.
Thus for each patient, there are ni pairs, (X1il, X2il), where the pairs may be correlated within patient. For
each lesion we calculate RCil =
X1il−X2il
X1il
. While several different correlation structures are theoretically
possible, we focus on the compound symmetric correlation structure which assumes that any two lesions
5
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within an individual have the same degree of correlation and this correlation is the same across all patients.
More formally, correlation(RCil,RCil′) = ρ for l 6= l′. We have found that this structure works reasonably
well in practice. Along the lines of what is suggested in [22], we can fit a random effects model to obtain the
estimated variance.
Let Yil = ln (1− RCil100 ). The model we fit is yil = µ+ bi + il where µ is the overall mean, bi ∼ N(0, σ2b )
is the subject random effect, and  ∼ N(0, σ2 ) is the residual error. To obtain the 95% LoA, calculate the
sample mean of Y , y¯. Fit the random effects model using any standard statistical software package. Add





 , to use as an estimate of the standard deviation of Y . Plug these estimates into the same
equation used above, 100× (1− ey¯±1.96s), to obtain the 95% LoA.
2.2.2. Patients as the unit of analysis
Using the same notation as above, here we sum across the lesions within a patient so that each patient
has only a single measure of the change in (total) tumor burden. The relative change in tumor burden for












With tumor measurements following a lognormal distribution, we are now faced with a ratio whose
numerator and denominator are sums of correlated lognormal random variables. It is a well-known fact that
the distribution of the sum of lognormal random variables does not have a closed form expression. However,
multiple people have shown that this distribution can be approximated by a lognormal distribution. One
frequently used approximation is the Fenton-Wilkonson approximation [25] which was developed for the
case when the summands are independent. This work was extended by Abu-Dayya and Beaulieu [26] to
accomodate correlated summands and later by Ligeti [27] to show that the distribution of the ratio of
correlated sums of lognormals is well-approximated by a lognormal distribution. Using these results and
reasoning similar to when there is one tumor per patient, the distribution of RCtotal is approximately
negative shifted lognormal.
To form the 95% LoA, let Y = ln (1 − RCtotal100 ). Calculate the sample mean of Y , y¯, and the sample




Fox and colleagues [28] studied patients with progressive prostate cancer who had multiple metastatic
bone and soft-tissue lesions. Briefly, as part of an IRB-approved protocol each patient was imaged with
PET/CT using two different radiotracers, FDG and 18F-16β-fluoro-dihydrotestosterone (FDHT). Both scans
were done within a 24-hour window in order to study the reproducibility of the measurements. More details
of the data collection, image acquisition, and co-registration of the scans from the two tracers can be found in
[28]. For this analysis we have data available on the SUVmax measurements for FDG-PET and FDHT-PET
on 167 lesions in 42 patients. The number of lesions per patient ranges from one to sixteen. Here we look at
the agreement between FDG-PET SUVmax and FDHT-PET SUVmax. Because there are multiple lesions
per patient, we first consider the agreement between measurements of each lesion individually and then the
agreement between the measurements of total tumor burden for each patient.
In Figure 1, we plot the SUVmax lesion measurement for both radiotracers. Note that the skewed shapes
of the histograms are consistent with lognormal distributions. Taking the SUVmax for FDG-PET to be X1
and the SUVmax for FDHT-PET to be X2 in the equations above, we calculate RCil at the lesion level and
plot the results in Figure 2a. With values of RCil ranging from -809% to 81%, this histogram demonstrates
clearly that RC does not follow a normal distribution. The Shapiro-Wilks test for normality suggests that
the distribution of Y = ln(1 − RC100 ) is consistent with a normal distribution (p=0.52), suggesting that the
negative lognormal distribution is a reasonable fit for RC estimated with this data.
To evaluate the agreement between the FDG-PET and FDHT-PET lesion measurements, we look at the
Bland-Altman plot displayed in Figure 3. The mean RC, -77.0%, is shown by the black dotted line. The 95%
LoA, (-485.3%, 69.6%), are shown by the black dashed lines. They suggest that the relative difference between
most pairs of FDG-PET and FDHT-PET SUVmax measurements taken from the same lesion at essentially
the same time will fall within this range. In other words, by changing the radiotracer from FDG to FDHT,
we might conclude that a lesion with no real change had a seemingly substantial decrease in metabolic
activity with an SUVmax decreasing by over 400%. Although there are no standard thresholds defining
response categories for nonanatomic imaging in the same way that RECIST defines response thresholds for
anatomic imaging, it has been suggested that a decrease of 30% in serial SUV measurements from FDG-PET
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is suggestive that a patient is having a partial response to treatment [6]. Placed within this context, Figure
3 very clearly indicates a lack of agreement between FDG-PET and FDHT-PET. For comparison, the grey
dashed-dotted lines demonstrate what would happen to the estimates of the LoA had we used the original
normal-based equations for the LoA that assume that the multiple lesions within a patient are independent
of one another. The resulting interval, (-378.8%, 224.8%), is markedly different particularly at the upper
bound of the interval which overestimates the increase we would expect to see even if there were no difference
in the lesion.
If we instead quantify the change in the SUV measurements at the patient level in terms of RCtotal,
the resulting values, shown in Figure 2(b), are skewed as expected. The Shapiro-Wilks test for Y suggests
data consistent with a normal distribution (p=0.83). The Bland-Altman plot looking at the agreement in
the measures of total tumor burden is shown in Figure 4. Even more important than the mean RCtotal of
-52.8%, the 95% LoA, (-382.1%, 68.7%), are again very wide and likely to suggest that a patient is responding
to treatment simply due to a switch in radiotracers. The LoA estimated by incorrectly assuming the RCtotal
follows a normal distribution, (-251.0%, 145.4%), while still indicating a large degree of variability are quite
different from the correctly estimated LoA.
4. Discussion
In looking at Figures 3 and 4, one may be struck by the observation that the LoA are not symmetric
around the mean. In the usual calculation of the LoA assuming normality, by definition the intervals are
symmetric reflecting the symmetric bell-shaped curve of the normal distribution. In contrast, it is precisely
because the RC and RCtotal have highly skewed distributions that a symmetric interval is not appropriate.
In the context of estimating confidence intervals for the mean of a lognormal distribution, it has been
shown in simulation studies [29, 30] that the usual 95% normal confidence interval can have a very large degree
of coverage error depending upon the sample size and severly underestimate the true coverage probability.
While the LoA are not confidence intervals, the same lessons apply. Incorrectly applying the LoA equations
based on the normality assumption to lognormal data will result in intervals that do not accurately capture
where 95% of the differences will lie.
A key point to interpretting Bland-Altman plots and the LoA is gauging how far apart measurements can
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be before it is decided that there is not sufficient agreement between the measurements. In our experience
as statisticians, we have frequently been asked to analyze data evaluating agreement between two anatomic
or nonanatomic measurements. We can easily produce Bland-Altman plots, but when we show the plots
to our radiology collaborators we find they often look to us to determine whether the level of agreement
is acceptable. As Bland and Altman very poignantly point out [21], this is not a statistical question but
a clinical one. Statisticians cannot answer this question in a vacuum and may be hard-pressed to provide
guidance to their clinical collaborators particularly when talking about differences in tumor measurements
on the absolute scale. In this situtation, we are fortunate to have a difference metric that is intimately
familiar to all radiologists who image cancer patients. It is a metric that can be directly related to patient
care and placed in the context of how the lack of agreement could affect patient management. We suggest
that basing Bland-Altman plots and correctly constructed LoA on this metric leads to evaluating agreement
on a naturally intuitive scale and helps to faciliate interpretation.
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5. Figure Legends
Figure 1. Histograms of SUVmax measurements for FDG-PET and FDHT-PET
Figure 2. Histograms showing the distribution of the relative change between SUVmax measurements for
FDG-PET and FDHT-PET at (a) the lesion level in terms of RC and (b) the patient level in terms of
RCtotal
Figure 3. Bland-Altman plot evaluating the agreement between SUVmax measurements from FDG-PET
and FDHT-PET for individual lesions. The dotted line shows the mean RC of -77.0% between the two
measurements. The black dashed lines show the 95% LoA, (-485.3%, 69.6%), calculated assuming the RC
follows a negative shifted lognormal distribution. The grey dashed-dotted lines demonstrate estimated 95%
LoA incorrectly calculated assuming the RC is normally distributed.
Figure 4. Bland-Altman plot evaluating the agreement between SUVmax measurements from FDG-PET
and FDHT-PET for total patient tumor burden. The dotted line shows the mean RCtotal of -52.8% between
the two measurements. The black dashed lines show the 95% LoA, (-382.1%, 68.7%), calculated assuming
the RCtotal follows a negative shifted lognormal distribution. The grey dashed-dotted lines demonstrate
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